Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MAINTENA KIT vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Not approved for pediatric use.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Hypersensitivity to aripiprazole or any excipients in the formulation.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
No interactions on record
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MAINTENA KIT vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MAINTENA KIT and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MAINTENA KIT and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.